{"url_path":"/sec/tnya/8-k/2026-07-02/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-294879-index.html","accession_number":"0001193125-26-294879","cik":"0001858848","ticker":"TNYA","issuer_name":"Tenaya Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1858848/0001193125-26-294879-index.html","primary_entity_key":"0001858848","primary_entity_name":"Tenaya Therapeutics, Inc."},"word_count":225,"has_tables":true,"body_markdown":"Item 1.02 Termination of a Material Definitive Agreement.\n\nOn June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenue, Union City, California 94587. The space served as the Company’s Genetic Medicines Manufacturing Center (the “GMMC Facility”), which the Company decommissioned in 2025 to reduce costs. Closure of the GMMC Facility is possible due to available inventory of TN-201 and TN-401 to support its ongoing clinical trials. The lease was originally scheduled to expire in July 2031, and will now terminate on August 31, 2026. As consideration for the lease termination, the Company agreed to forfeit its $1,750,000 security deposit and pay a one-time lease termination fee of approximately $294,200.\n\nThe Company has retained its internal process and assay development know-how and plans to transfer its AAV manufacturing process to a contract development manufacturing organization with global capabilities in anticipation of future late-stage development and/or commercial launch of TN-201 and/or TN-401.\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nTENAYA THERAPEUTICS, INC.\n\n \n\n \n\n \n\nBy:\n\n \n\n \n\n/s/ Jennifer Drimmer Rokovich\n\n \n\n \n\n \n\n \n\nJennifer Drimmer Rokovich\n\n \n\n \n\n \n\n \n\nGeneral Counsel and Secretary\n\nDate: July 2, 2026"}